GlassScriptPhysician profile
Soo Mee Pak
NPI 1851482228
$13,167.73
in general payments reported to CMS, 2019-2025
33 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,909 · 2020: $679 · 2021: $1,347 · 2022: $1,121 · 2023: $1,218 · 2024: $2,796 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,093 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,093.19 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $3,165.92 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Glaukos Corporation | $2,354.91 | 2019-2025 | Idose, Idosetr, Istent |
| Alcon Vision LLC | $1,390.04 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $1,090.73 | 2022-2025 | Envista Mx60 Iol, Miebo, Envista Aspire Iol |
| Sun Pharmaceutical Industries INC. | $992.27 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $747.51 | 2019-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $491.33 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $418.04 | 2019-2021 | |
| Allergan, INC. | $381.55 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $358.50 | 2019-2021 | |
| New World Medical,INC. | $279.16 | 2021-2023 | |
| Rxsight INC | $143.07 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Shire North American Group INC | $139.75 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $137.39 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $135.02 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $120.72 | 2024-2025 | Tepezza |
| Abbvie INC. | $118.05 | 2023-2025 | |
| Ocular Therapeutix, INC. | $103.04 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $99.69 | 2022 | |
| Oyster Point Pharma, INC. | $66.81 | 2024-2025 | Ryzumvi, Tyrvaya |
| Smith+Nephew, INC. | $66.71 | 2020 | |
| Novartis Pharmaceuticals Corporation | $66.28 | 2019-2022 | |
| Coopervision INC. | $54.13 | 2022-2024 | Myday Contact Lens |
| Thea Pharma INC. | $37.43 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $34.53 | 2024-2025 | Vevye |
| Dompe US, INC. | $30.52 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $29.20 | 2025 | |
| Rayner Intraocular Lenses Limited | $24.52 | 2025 | Omidria |
| Horizon Therapeutics Plc | $22.59 | 2023 | Tepezza |
| Astellas Pharma US INC | $20.98 | 2024 | Izervay |
| Ivantis, INC | $20.09 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.79 | 2021 | |
| Optos, INC. | $9.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soo Mee Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.